Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension

Study Identifier
192024-094
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Study Details

Medical Condition
  • Glaucoma - Open Angle
  • Ocular Hypertension
  • Study Drug
  • bimatoprost 0.03% plus timolol 0.5%
  • Phase
    Phase 4
    Sex
    Female & Male
    Age
    18+ years

    Protocol Summary

    A study to evaluate the long-term safety of GANFORT® (bimatoprost 0.03% plus timolol 0.5%) in Chinese patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blocker or prostaglandin analogues.

    Study Locations

    Location
    Status
    Location
    Beijing Hospital
    Beijing, Beijing Municipality, China, 100005
    Status
    Not applicable
    Location
    Xuanwu Hospital Capital Medical University
    Beijing, Beijing Municipality, China, 100053
    Status
    Not applicable
    Location
    Peking University Third Hospital
    Beijing, Beijing Municipality, China, 100191
    Status
    Not applicable
    Location
    Beijing Tongren hospital Capital Medical University
    Beijing, Beijing Municipality, China, 100730
    Status
    Not applicable
    Location
    Zhongshan Ophthalmic Center, Sun Yat-Sen University
    Guangzhou, Guangdong, China, 510060
    Status
    Not applicable
    Location
    Tongji Hospital of Tongji Medical College, Huazhong University of Science & Technology
    Wuhan, Hubei, China, 430030
    Status
    Not applicable
    Showing {first} - {last} of {total} Results